Skip to main content
. Author manuscript; available in PMC: 2024 Dec 8.
Published in final edited form as: Nature. 2021 Mar 11;593(7857):136–141. doi: 10.1038/s41586-021-03412-7

Figure 1. Neutralization by first and second dose mRNA vaccine sera against wild type and B.1.1.7 Spike mutant SARS-CoV-2 pseudotyped viruses.

Figure 1

a, Spike in open conformation with a single erect RBD (PDB: 6ZGG) in trimer axis vertical view with the locations of mutated residues highlighted in red spheres and labelled on the monomer with erect RBD. Vaccine first dose (b-c, n=37), second dose (d-e, n=21) and convalescent sera, Conv. (f-g,n=27) against WT and B.1.1.7 Spike mutant with N501Y, A570D, ΔH69/V70, Δ144/145, P681H, T716I, S982A and D1118H. GMT with s.d presented of two independent experiments each with two technical repeats. Wilcoxon matched-pairs signed rank test p-values * <0.05, ** <0.01, ***<0.001, **** <0.0001, ns not significant HS – human AB serum control. Limit of detection for 50% neutralization set at 10.